Skip to content

Trial Summary

To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Acronym:

AMG 650

ACTRN/NCT /ethics:

NCT04293094

Scientific title:

A Phase 1, Multicenter, Open-label, Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects with Advanced Solid Tumors (protocol number 20190131).

Sponsor / Cooperative group:

Amgen

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2020-03-12
Anticipated End Date2023-10-01

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6410
Principal InvestigatorDr Amanda Townsend
Recruitment StatusRecruiting